AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Athira Pharma Executives' Stock Trades: Buy and Sell Activity
ByAinvest
Wednesday, Jul 2, 2025 4:41 pm ET1min read
Athira Pharma, Inc. [ATHA] recently disclosed insider transactions involving key executives. Chief Scientific Officer Kevin Church sold 8,526 shares at $0.29 per share on July 1, 2025, while Director, President and CEO Mark James Litton sold 25,123 shares at the same price on the same date. SVP of Finance and Accounting Robert Renninger sold 2,897 shares at $0.29 per share on July 1, 2025, and also purchased 10,000 shares at $0.23 per share on May 19, 2025. Chief Medical Officer Javier San Martin sold 10,842 shares at $0.29 per share on July 1, 2025, and General Counsel and CCO Mark Worthington sold 8,526 shares at $0.29 per share on the same date.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet